{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=22", "query": { "condition": "Carcinoma of Head/Neck", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 1991, "total_pages": 200, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T21:34:50.228Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02277197", "title": "Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Squamous Cell of Head and Neck", "Squamous Cell Carcinoma of the Head and Neck", "Squamous Cell Carcinoma, Head And Neck" ], "interventions": [ { "name": "Ficlatuzumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James J Lee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-08", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 3, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277197" }, { "nct_id": "NCT01811212", "title": "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Stage I Thyroid Gland Follicular Carcinoma", "Stage I Thyroid Gland Papillary Carcinoma", "Stage II Thyroid Gland Follicular Carcinoma", "Stage II Thyroid Gland Papillary Carcinoma", "Stage III Thyroid Gland Follicular Carcinoma", "Stage III Thyroid Gland Papillary Carcinoma", "Stage IVA Thyroid Gland Follicular Carcinoma", "Stage IVA Thyroid Gland Papillary Carcinoma", "Stage IVB Thyroid Gland Follicular Carcinoma", "Stage IVB Thyroid Gland Papillary Carcinoma", "Stage IVC Thyroid Gland Follicular Carcinoma", "Stage IVC Thyroid Gland Papillary Carcinoma", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Oncocytic Follicular Carcinoma" ], "interventions": [ { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2013-05-08", "completion_date": "2017-10-09", "has_results": true, "last_update_posted_date": "2018-04-03", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Jacksonville, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01811212" }, { "nct_id": "NCT06088381", "title": "Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma", "Oropharynx Cancer", "Oropharynx Squamous Cell Carcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Experimental Observation", "type": "OTHER" }, { "name": "Observation per Standard of Care", "type": "OTHER" }, { "name": "Adjuvant Treatment per Standard of Care", "type": "RADIATION" }, { "name": "Circulating Tumor DNA test (ctDNA test)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "OTHER", "RADIATION", "DIAGNOSTIC_TEST" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2024-03-07", "completion_date": "2030-12-18", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bel Air", "state": "Maryland" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Glen Burnie", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06088381" }, { "nct_id": "NCT05319730", "title": "A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "H2 Receptor Antagonist", "type": "DRUG" }, { "name": "Acetaminophen (or equivalent)", "type": "DRUG" }, { "name": "Dexamethasone (or equivalent)", "type": "DRUG" }, { "name": "Steroid Mouthwash (dexamethasone or equivalent)", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2023-05-16", "completion_date": "2029-04-10", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 5, "location_summary": "Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "East Syracuse", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319730" }, { "nct_id": "NCT03347123", "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Lirilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-03-21", "completion_date": "2021-01-29", "has_results": true, "last_update_posted_date": "2022-02-28", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03347123" }, { "nct_id": "NCT06693323", "title": "Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HNSCC", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "AHCC®capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 34, "start_date": "2024-12-04", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-03-27", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06693323" }, { "nct_id": "NCT02749903", "title": "Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Androgen Receptor Positive", "Locally Advanced Salivary Gland Carcinoma", "Metastatic Salivary Gland Carcinoma", "Salivary Duct Carcinoma", "Salivary Gland Adenocarcinoma, NOS", "Salivary Gland Basal Cell Adenocarcinoma", "Stage III Major Salivary Gland Cancer AJCC v7" ], "interventions": [ { "name": "enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2016-09-14", "completion_date": "2028-07-05", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 287, "location_summary": "Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 201 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02749903" }, { "nct_id": "NCT06984861", "title": "A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharyngeal Carcinoma" ], "interventions": [ { "name": "18F-FMISO PET/CT Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Chemoradiation", "type": "COMBINATION_PRODUCT" }, { "name": "Questionnaires", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2025-05-13", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06984861" }, { "nct_id": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Volrustomig", "type": "BIOLOGICAL" }, { "name": "Rilvegostomig", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 452, "start_date": "2020-06-03", "completion_date": "2027-05-04", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04379596" }, { "nct_id": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Colorectal Carcinoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "ABBV-221", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 46, "start_date": "2015-01-09", "completion_date": "2018-03-15", "has_results": false, "last_update_posted_date": "2018-03-30", "last_synced_at": "2026-10-15T21:34:50.228Z", "location_count": 3, "location_summary": "Boston, Massachusetts • San Antonio, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02365662" } ] }